Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood. Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

Produk Detail:

  • Author : Tarik F. Massoud
  • Publisher : Academic Press
  • Pages : 350 pages
  • ISBN : 9780128215678
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKGlioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies
  • Author : Tarik F. Massoud,Ramasamy Paulmurugan
  • Publisher : Academic Press
  • Release : 15 March 2021
GET THIS BOOKGlioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists,

Cancer Drug Resistance

Cancer Drug Resistance
  • Author : Beverly A. Teicher
  • Publisher : Springer Science & Business Media
  • Release : 09 November 2007
GET THIS BOOKCancer Drug Resistance

Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies,

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy
  • Author : Benjamin Bonavida
  • Publisher : Springer Science & Business Media
  • Release : 04 July 2013
GET THIS BOOKMolecular Mechanisms of Tumor Cell Resistance to Chemotherapy

​​​​​This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order

Alternative Mechanisms of Multidrug Resistance in Cancer

Alternative Mechanisms of Multidrug Resistance in Cancer
  • Author : John A. Kellen
  • Publisher : Springer Science & Business Media
  • Release : 06 December 2012
GET THIS BOOKAlternative Mechanisms of Multidrug Resistance in Cancer

Nullius in verba. . . Truth will be tested not by words. Horace (Epistles) Few read introductions except for book reviewers, who want to take a shortcut and avoid reading the book itself. However, tradition requires that the preface make public why the book was written at all (this is not supposed to include powerful reasons such as augmenting the ego of the editor and authors). Frequently, the inflationary tendency to publish in verbose length is in conflict with market forces and

Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy

Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy
  • Author : Pawel Kalinski
  • Publisher : Springer
  • Release : 22 December 2017
GET THIS BOOKTumor Immune Microenvironment in Cancer Progression and Cancer Therapy

The tumor microenvironment has become a very important and hot topic in cancer research within the past few years. The tumor microenvironment is defined as the normal cells, molecules, and blood vessels that surround and feed a tumor cell. As many scientists have realized, studying the tumor microenvironment has become critical to moving the field forward, since there are many players in a tumor’s localized and surrounding area, which can significantly change cancer cell behavior. There is a dual

Macromolecular Anticancer Therapeutics

Macromolecular Anticancer Therapeutics
  • Author : L. Harivardhan Reddy,Patrick Couvreur
  • Publisher : Springer Science & Business Media
  • Release : 20 March 2010
GET THIS BOOKMacromolecular Anticancer Therapeutics

In spite of the development of various anticancer drugs, the therapy of cancer has remained challenging for decades. The current therapy of cancer is overwhelmed because of the inability to deliver therapeutics to all regions of a tumor in effective therapeutic concentrations, intrinsic or acquired resistance to the treatment with currently available agents via genetic and epigenetic mechanisms, and toxicity. As a result, cancer therapy using conventional therapeutics and different types of treatment regimens using this therapeutics has not led

PIPAC

PIPAC
  • Author : Marc A. Reymond,Wiebke Solass
  • Publisher : Walter de Gruyter GmbH & Co KG
  • Release : 14 October 2014
GET THIS BOOKPIPAC

Peritoneal dissemination is a common route of cancer metastasis. The benefit of administering chemotherapy directly into the peritoneal cavity is supported by preclinical and pharmacokinetic data. In comparison to intravenous (IV) treatment, intraperitoneal (IP) administration results in a several-fold increase in drug concentration within the abdominal cavity. There is now growing evidence from clinical studies showing a survival advantage for IP chemotherapy in various tumor typies, including ovarian, gastric and colorectal cancer. However, while the use of IP chemotherapy is

Tumor Progression and Therapeutic Resistance

Tumor Progression and Therapeutic Resistance
  • Author : Wafik S. El-Deiry
  • Publisher : Unknown Publisher
  • Release : 28 February 2021
GET THIS BOOKTumor Progression and Therapeutic Resistance

This volume presents the entire breadth of translational cancer research and brings together members of academia and industry in the expectation of accelerating interactions and progress in the field. A variety of key topics are presented, beginning with discovery of molecular targets and pathways (oncogene, cell survival, tumor suppression, cell death), host-neoplasm interactions (cell adhesion, matrix proteases), early detection, monitoring progression, understanding tumor progression and metastasis, immune surveillance, in vivo molecular imaging, animal models, drug discovery including chemistry, high-throughput assays,

Immunotherapy of Cancer

Immunotherapy of Cancer
  • Author : Yoshiyuki Yamaguchi
  • Publisher : Springer
  • Release : 22 February 2016
GET THIS BOOKImmunotherapy of Cancer

This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments

Nanotheranostics for Cancer Applications

Nanotheranostics for Cancer Applications
  • Author : Prakash Rai,Stephanie A. Morris
  • Publisher : Springer
  • Release : 12 November 2018
GET THIS BOOKNanotheranostics for Cancer Applications

This book is the first to focus specifically on cancer nanotheranostics. Each of the chapters that make up this comprehensive volume is authored by a researcher, clinician, or regulatory agency member known for their expertise in this field. Theranostics, the technology to simultaneously diagnose and treat a disease, is a nascent field that is growing rapidly in this era of personalized medicine. As the need for cost-effective disease diagnosis grows, drug delivery systems that can act as multifunctional carriers for

Biotechnology and Production of Anti-Cancer Compounds

Biotechnology and Production of Anti-Cancer Compounds
  • Author : Sonia Malik
  • Publisher : Springer
  • Release : 21 April 2017
GET THIS BOOKBiotechnology and Production of Anti-Cancer Compounds

This book discusses cancers and the resurgence of public interest in plant-based and herbal drugs. It also describes ways of obtaining anti-cancer drugs from plants and improving their production using biotechnological techniques. It presents methods such as cell culture, shoot and root culture, hairy root culture, purification of plant raw materials, genetic engineering, optimization of culture conditions as well as metabolic engineering with examples of successes like taxol, shikonin, ingenol mebutate and podophylotoxin. In addition, it describes the applications and

Cancer Gene Therapy

Cancer Gene Therapy
  • Author : David T. Curiel,Joanne T. Douglas
  • Publisher : Springer Science & Business Media
  • Release : 03 November 2007
GET THIS BOOKCancer Gene Therapy

A complete introduction and guide to the latest developments in cancer gene therapy-from bench to bedside. The authors comprehensively review the anticancer genes and gene delivery methods currently available for cancer gene therapy, including the transfer of genetic material into the cancer cells, stimulation of the immune system to recognize and eliminate cancer cells, and the targeting of the nonmalignant stromal cells that support their growth. They also thoroughly examine the advantages and limitations of the different therapies and detail

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies
  • Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
  • Publisher : Springer
  • Release : 15 July 2019
GET THIS BOOKCurrent Applications for Overcoming Resistance to Targeted Therapies

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians